MaxCyte appoints Cynthia Collins to Board; board expands to 10 members

MAXCYTE, INC.

Cynthia Collins appointed as Class II director effective Oct 14, 2024; board expands from 9 to 10.
Collins to serve on Compensation Committee; receives 97,698 stock options (3-yr vest) and 51,679 RSUs (1-yr vest).
Over 40 years biotech experience, including CEO of Editas Medicine; boards of Poseida (PSTX), Certara (CERT), and others.
Disclosure notes past directorship at DermTech (OTC:DMTKQ) which filed Chapter 11 in June 2024; no other regulatory issues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.